What is Brigham/Faulkner Ob/Gyn?
Operating as a critical affiliate of Brigham & Women's Hospital, Brigham/Faulkner Ob/Gyn provides a comprehensive suite of obstetrical and gynecological services tailored to women across all life stages. The practice distinguishes itself through a blend of traditional prenatal care and advanced, minimally invasive surgical interventions. Notably, the integration of cutting-edge medical technologies, such as the Sonata Treatment for uterine fibroids, positions the firm at the forefront of gynecological innovation. Their market position is defined by a dual focus on patient-centric care and the adoption of evidence-based, high-efficacy treatment protocols that address complex reproductive health challenges.
How much funding has Brigham/Faulkner Ob/Gyn raised?
Brigham/Faulkner Ob/Gyn has raised a total of $488K across 2 funding rounds:
Debt
$150K
Debt
$338K
Debt (2020): $150K with participation from PPP
Debt (2021): $338K led by PPP
Key Investors in Brigham/Faulkner Ob/Gyn
PPP
Public-Private Partnership
What's next for Brigham/Faulkner Ob/Gyn?
With the recent infusion of capital, Brigham/Faulkner Ob/Gyn is well-positioned to accelerate its operational growth and enhance its service delivery infrastructure. The strategic deployment of these funds will likely focus on scaling the availability of specialized procedures and potentially expanding the practice's footprint to meet the rising demand for sophisticated women's health services in the greater Boston area. As the organization navigates this late-stage growth phase, the emphasis will remain on maintaining clinical excellence while optimizing patient outcomes through continued investment in medical technology and specialized staff expertise.
See full Brigham/Faulkner Ob/Gyn company page
